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Citrullinated Calreticulin Potentiates Rheumatoid Arthritis
Shared Epitope Signaling
Song Ling, Erika N. Cline, Timothy S. Haug, David A. Fox, and Joseph Holoshitz
Objective. Citrullinated proteins are immuno-
genic in rheumatoid arthritis (RA), particularly in
patients who carry shared epitope (SE)–coding HLA–
DRB1 alleles. The mechanism underlying this associa-
tion is unknown. We have previously identified the SE
as a ligand that interacts with cell surface calreticulin
(CRT) and activates immune dysregulation. This study
was undertaken to determine the effect of CRT citrulli-
nation on SE signaling.
Methods. CRT–SE binding affinity was measured
by surface plasmon resonance. The role of individual
CRT arginine residues was determined by site-directed
mutagenesis, and nitric oxide levels were measured
using a fluorochrome-based assay. CRT citrullination
in synovial tissue samples and cell cultures was deter-
mined by 2-dimensional gel electrophoresis, immuno-
blotting, and mass spectrometry techniques.
Results. Synovial tissue and fibroblast-like syno-
viocytes from RA patients were found to express a
higher abundance of citrullinated CRT than samples
from osteoarthritis patients. Citrullinated CRT showed
more robust interaction with the SE ligand, and trans-
duced SE signaling at a 10,000-fold higher potency,
compared to noncitrullinated CRT. Site-directed muta-
tion analysis identified Arg205, which is spatially adja-
cent to the SE binding site in the CRT P-domain, as a
dominant inhibitor of SE–CRT interaction and signal-
ing, while a more remote arginine residue, Arg261, was
found to enhance these SE functions.
Conclusion. Our findings indicate that citrulli-
nated CRT is overabundant in the RA synovium and
potentiates SE-activated signaling in vitro. These find-
ings could introduce a new mechanistic model of gene–
environment interaction in RA.
The shared epitope (SE), a 5–amino acid se-
quence motif in positions 70–74 of the HLA–DR
chain, is the most significant genetic risk factor for
rheumatoid arthritis (RA) (1,2). The disease is more
erosive in individuals carrying SE-coding HLA–DRB1
alleles than in SE-negative individuals (3). The mecha-
nism underlying the effect of the SE in RA is unknown.
We have recently identified the SE as a ligand that
activates innate signaling and Th17 polarization (4–7).
Whether expressed in its native conformation on the cell
surface, as a cell-free HLA–DR tetrameric molecule,
engineered into large recombinant proteins, or as a short
synthetic peptide, the SE activates nitric oxide (NO)
production in a strictly allele-specific manner. SE-
activated signaling is transduced via cell surface calreti-
culin (CRT) (6), an established innate immunity recep-
tor. Using a point mutagenesis technique, we have
recently mapped the SE binding site to amino acid
residues Glu217, Asp220, and Glu223 in the CRT
P-domain (8).
Although genetic factors strongly influence dis-
ease risk, the concordance rate of RA in identical twins
is only 15% (9). It has therefore been proposed that
while susceptibility is determined genetically, disease
onset may depend on environmentally triggered stochas-
tic events, such as posttranslational protein modifica-
tions (for review, see ref. 10). One of the better-known
protein modifications in RA involves deimination of
arginine residues to citrulline by peptidyl arginine deimi-
nase (PAD). Citrullinated proteins are overabundant in
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RA joints, as well as many other inflammatory tissues,
such as the brain in patients with multiple sclerosis,
muscle in patients with myositis, or the gut in patients
with Crohn’s disease (11,12).
Several citrullinated proteins have been identi-
fied in RA (13–15), and some of them have been found
to be targets of anti–citrullinated protein antibodies
(ACPAs), which are useful biomarkers for RA (for
review, see ref. 16). Although the pathogenic role of
ACPAs in human RA remains an open question, it is
well established that these antibodies are more com-
monly found in SE-positive RA patients (16). Further-
more, an SE gene-dose effect on RA risk has been
documented in ACPA-positive RA patients (17).
Thus, RA development involves an intricate re-
lationship between genetic (notably SE) and acquired,
nongenetic (protein citrullination) factors. Several stud-
ies have identified synergism between SE and smoking
in RA (18–20), and an association between smoking and
pulmonary PAD-2 expression, supporting the hypothesis
that smoking-induced PAD activation may trigger the
onset of an SE-driven disease (21).
Given the known association of the SE with RA,
its recently discovered signaling effect via CRT, the
association of protein citrullination with the disease, and
the interaction between the SE and a citrullination-
driven RA biomarker, we have sought to determine
whether CRT citrullination affects SE signaling. Here
we demonstrate that citrullinated CRT (Cit-CRT) has
higher affinity for the SE ligand with resultant potenti-
ation of SE-activated signaling. Using point mutagene-
sis, we have identified 3 arginine residues in CRT that
modulate SE binding to CRT and, consequently, the
potency of its signaling. Finally, we demonstrate that
Cit-CRT is overabundant in RA synovial tissue. These
results provide new insights into the functional effect of
the SE and identify a candidate molecular basis for a
mechanistic model of gene–environment interaction in
RA.
MATERIALS AND METHODS
Cells and reagents. The mouse embryonic fibroblast
(MEF) line K42, isolated from crt/ mice, has been described
previously (22). Diaminofluorescein diacetate (DAF-2 DA)
was purchased from EMD Calbiochem. SE ligands were
expressed as either 15-mer synthetic peptides (65–79*0401 or
65–79*0402) or in the form of HLA–DR4 tetramers as previ-
ously described (4–8). All other chemicals were from Sigma.
Fibroblast-like synoviocytes (FLS) were prepared as previously
described (22) from synovial tissue obtained from patients with
RA or osteoarthritis (OA) who were undergoing joint replace-
ment surgery at the University of Michigan Health system.
FLS were used between passages 4 and 8. Patients classified as
having RA satisfied the 1987 American College of Rheuma-
tology criteria (23). The presence of OA was ascertained by
clinical diagnosis and characteristic findings on radiographs.
Procedures involving human subjects were conducted under an
institutional review board–approved protocol.
Generation of CRT point mutants. Site-directed mu-
tagenesis was performed following the QuikChange protocol
(Stratagene). Sequences were verified by the University of
Michigan DNA Sequencing Core. Mouse wild-type CRT and
its site-directed mutants were cloned into pBAD/glll A-His6
plasmid as previously described (24). Wild-type and mutant
CRT plasmids were transformed into GC10 cells for protein
expression. The 6 His–tagged protein expression was in-
duced by incubation with 0.002% L-arabinose for 4 hours, and
the protein was purified using a nickel–nitrilotriacetic acid
resin following the recommendations of the manufacturer
(Qiagen).
In vitro citrullination of CRT. Purified mouse CRT
was incubated with 2 units of PAD from rabbit skeleton muscle
in the reaction buffer (0.1M Tris HCl, pH7.6, 10 mM CaCl2, 5
mM dithioerythritol, and 1 proteinase inhibitor cocktail) for
16 hours at 37°C (25). At the end of incubation, the reaction
mixture was loaded onto 10% sodium dodecyl sulfate (SDS)–
polyacrylamide gel electrophoresis gel. The CRT band was
in-gel digested by Glu-c. Then citrullination sites on CRT were
confirmed using an LTQ Orbitrap XL (as described below) at
the Proteomic Resource Facility in the Department of Pathol-
ogy, University of Michigan.
Surface plasmon resonance. A BIAcore 2000 instru-
ment (GE Healthcare) was used as previously described (6,8).
All assays were performed at 25°C in a binding buffer contain-
ing 10 mM HEPES (pH 7.4), 50 mM KCl, 0.5 mM CaCl2, 100
M ZnCl2, and 0.005% Surfactant P20. The analyte was
injected at a flow rate of 10 l/minute.
Chemical modification of citrulline residues. Cell ly-
sates were chemically modified in reaction mixture with 8.3
mM antipyrine, 50% trifluoroacetic acid, and 8.3 mM 2,3-
butanedione, as previously described (26). The mixture was
incubated for 2 hours at 37°C in the dark. At the end of
modification, the reaction mixture leftover was removed by
desalting column. The chemically modified cell lysates were
processed by immunoprecipitation.
Mass spectrometry (MS). MS analysis of in vitro
citrullinated CRT was performed by the liquid chromatogra-
phy electrospray ionization MS/MS method at the Proteomic
Resource Facility in the Department of Pathology, University
of Michigan. Peptide samples were suspended in 1% acetic
acid and 2% acetonitrile, and loaded onto a reverse-phase
separation column (0.075  100 mm) packed in house with
MAGIC C18 AQ 5 m (Michrom Bioresources). The peptides
were separated on a 1% acetic acid/acetonitrile gradient
system (5–50% acetonitrile for 75 minutes, followed by a 10
minute 95% acetonitrile wash) at a flow rate of 300 nl/
minute. Peptides were directly sprayed onto the MS using a
nanospray source. An LTQ Orbitrap XL (Thermo Fisher
Scientific) was run in automatic mode collecting a high-
resolution MS scan (full-width half-maximum 30,000) followed
by data-dependent acquisition of MS/MS scans on the 9 most
intense ions (relative collision energy 35%). Dynamic exclu-
sion was set to collect 2 MS/MS scans on each ion and exclude
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it for an additional 2 minutes. Charge state screening was
enabled to exclude 1 and undetermined charge states (27).
Raw data were searched against the UniProt mouse protein
database (released May 2011) appended with reverse se-
quences using the X!Tandem/TPP software suite. Carbam-
idomethylation of cysteine (57.0214 daltons), oxidation of
methionine (15.9949 daltons), and citrullination of arginine
(0.9840 daltons) were considered as potential modifications.
Precursor mass tolerance of 50 parts per million, and fragment
mass tolerance of 0.5 daltons were allowed. Peptides contain-
ing citrullinated arginine with a PeptideProphet probability of
0.9 were considered positive and manually verified.
To identify CRT citrullination sites in synovial tissue
and FLS, mass spectrometric analysis of chemically modified
citrulline residues was performed at the University of Michi-
gan Proteome Mapping Core. The matrix-assisted laser de-
sorption ionization–time-of-flight/time-of-flight mass spectra
of chymotrypsin-digested peptide were obtained using an
Applied Biosystems 4800 Proteomics Analyzer, as previously
described (8).
Immunoprecipitation analysis. Tissue or cell lysates
were precleared by incubation with protein G–agarose beads
(Sigma) for 15 minutes at 4°C. The precleared part was then
incubated overnight with beads and a 1:25 dilution of mouse
anti-CRT antibody (Becton Dickinson). Beads were then
washed once with radioimmunoprecipitation assay buffer and
twice with phosphate buffered saline, and the immune com-
plexes were released from the beads by boiling in sample buffer
for 5 minutes. Following SDS–polyacrylamide gel electrophor-
esis, immunoprecipitated products were analyzed by Western
blotting using anticitrulline antibody (Abcam). The CRT level
on the same blot was confirmed by rabbit anti-CRT antibody
(Pierce).
Two-dimensional gel electrophoresis (2-DE). RA and
OA FLS were analyzed by Western blotting using 2-DE
membranes. Proteins were focused at 20°C, with 11 cm, pH
3–5.6, immobilized pH gradient ReadyStrip IPG strips (Bio-
Rad), which had been incubated in 200 l protein extract
mixed with rehydration buffer (8M urea, 2% CHAPS, 1%
dithiothreitol [DTT], trace of bromophenol blue, 0.2% Biolyte
carrier ampholytes [pH 3–5.6]) (Bio-Rad) for 16 hours. A
Protean IEF cell (Bio-Rad) was used with fast-voltage ramping
at a maximum voltage of 6,000V for 20 hours. After the
first-dimension run, the strips were equilibrated by incubation
in 6M urea, 0.375M Tris HCl (pH 8.8), 2% SDS, 20% glycerol,
2.5% weight/volume DTT at 10 ml per strip for 20 minutes at
room temperature, followed by an incubation for 30 minutes in
the same buffer but in which DTT was replaced by 2.5% w/v
iodoacetamide. Strips were then placed on the top of 4–12%
Criterion XT precast gels (11 cm  8 cm  1 mm) (Bio-Rad)
and migrated constantly at 200V until the bromophenol blue
dye front had reached the bottom of the gel. A BenchMark
prestained protein ladder (Invitrogen) was used as the molec-
ular weight standard in the second-dimension step. Finally,
gels were either stained with Sypro Ruby protein gel stain
(Bio-Rad) or were electroblotted onto nitrocellulose mem-
branes. Sypro Ruby–stained 2-D gels were scanned using a
densitometer, and Western blotting analyses were performed.
Signal transduction assays. To measure NO produc-
tion, crt/ MEF were seeded in a 96-well plate at 30,000 cells
per well. Cultures were loaded with recombinant WT or
mutant CRT overnight. Cells were then labeled by 20 M
DAF-2 DA for 1 hour and stimulated with SE ligands. NO
production rates were determined as previously described
(4–8).
Statistical analysis. Data are expressed as the mean 
SEM from triplicate samples. Statistical analyses were per-
formed using Student’s 2-tailed t-test.
RESULTS
CRT citrullination enhances SE–CRT interac-
tion and potentiates SE-activated signaling. RA epide-
miology and translational research findings strongly
suggest that while RA susceptibility is determined ge-
netically, disease onset may depend on environmentally
triggered stochastic events, such as posttranslational
protein modifications. Given the growing evidence for
aberrant protein citrullination in RA, we first examined
whether citrullination of CRT could affect the functional
properties of the SE.
Recombinant CRT was citrullinated in vitro as
previously reported (25). To determine the effect of
global CRT citrullination on its interaction with the SE,
Cit-CRT or native CRT proteins were immobilized on
biosensor chips and their binding affinities toward SE
peptides, or SE-expressing HLA–DR tetramers, were
determined. As can be seen in Figure 1, the SE ligand
65–79*0401 (a 15-mer peptide corresponding to the
65–79 region, coded by an SE-positive allele, DRB1*04:
01) interacted more potently with Cit-CRT than with
native CRT. A control peptide, 65–79*0402 (corre-
sponding to the 65–79 region, coded by an SE-negative
allele, DRB1*04:02), did not bind to either native CRT
or Cit-CRT. The SE-positive HLA tetramer T-0401 (4
units of heterodimeric molecules, each made of a DR
chain coded by allele HLA–DRB1*04:01 and a DR
chain coded by HLA–DRA1) showed markedly higher
interaction with Cit-CRT than with native CRT. A
control, SE-negative tetramer T-1501, did not bind to
native CRT and did not show preferential binding to
Cit-CRT (Figure 1B). Kinetics analysis (Table 1) re-
vealed that Cit-CRT had 100-fold higher affinity (KD)
for the SE ligand compared with native CRT. Impor-
tantly, the affinity of C1q, another CRT ligand, was
unaffected by citrullination. Thus, we conclude that
global citrullination of CRT potentiates its interaction
with the SE ligand.
We next performed experiments to determine
whether increased affinity in cell-free binding studies
has functional correlates in signal transduction assays.
We (6,8) and others (28,29) have previously demon-
strated that when soluble CRT is added to CRT-
negative cells it attaches to the cell surface and restores
CRT receptor–mediated signaling. Accordingly, to de-
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termine the effect of CRT citrullination on signal trans-
duction, soluble native CRT or Cit-CRT proteins were
added to CRT-deficient cells, followed by stimulation
with the SE ligand. As can be seen, Cit-CRT mediated
signal transduction much more effectively. It transduced
SE signaling at significantly lower receptor concentra-
tions (Figure 1C) and at a much lower ligand concen-
tration threshold (Figure 1D) than the native CRT. The
50% maximum response concentration of SE with Cit-
CRT (2.45  107) was 10,000-fold lower than that with
native CRT (2.05  103).
It is worth noting that, unlike native CRT, Cit-
CRT transduced much more potent SE-activated signals
when added to tissue cultures at lower concentrations
(Figure 1C). The reason for this “paradoxical” dose-
response curve is unclear. One possible explanation is
that at high tissue culture concentrations, there is satu-
ration of the CRT-anchoring sites at the cell surface,
with resultant higher abundance of free Cit-CRT in the
supernatant. Due to its higher affinity, unbound Cit-
CRT could conceivably “intercept” the SE ligand before
it binds to the cell surface–anchored signal-transducing
receptor.
The impact of individual arginine residues.
Given that citrullination involves conversion of posi-
tively charged arginine residues to neutrally charged
citrullines, we sought to determine whether the aug-
mented interaction between the SE and Cit-CRT de-
scribed above can be attributed to a loss of positive
charge near the SE binding site, previously mapped to
the CRT P-domain (8). Of the 8 arginine residues in the
mature CRT protein, only Arg205 and Arg261 are located
in its P-domain. Another remote, but possibly spatially
relevant, residue is Arg160, located in the CRT
N-domain, close to its junction with the P-domain. MS
Table 1. Kinetics of CRT–ligand interactions*
Native CRT Cit-CRT
65–79*0401
Ka (1/M  second) 8.7  6.2 560  0.4
Kd (1/second) 8.2  2.1  10
4 5.1  0.2  105
KD (M) 9.6  3.8  10
6 8.4  0.3  108
C1q
Ka (1/M  second) 1.7  2.0  10
5 2.7  0.5  105
Kd (1/second) 2.8  0.2  10
4 2.4  0.4  104
KD (M) 1.7  0.2  10
9 9.0  1.1  1010
* Values are the mean  SEM. CRT  calreticulin.
Table 2. MS analysis of CRT citrullination sites*
Origin Citrullinated sites
Recombinant protein†
Mouse Crt Arg19, Arg160 , Arg205, Arg261
FLS‡
RA1 Arg19, Arg56, Arg145




RA3 Arg56, Arg145, Arg205
RA4 Arg19 , Arg56, Arg145, Arg205
RA5 Arg19, Arg205 , Arg261
OA3 Arg56, Arg145, Arg160 , Arg205
OA4 Arg19, Arg56, Arg145, Arg160, Arg205, Arg261
* FLS  fibroblast-like synoviocyte; RA1  rheumatoid arthritis
patient 1; OA1  osteoarthritis patient 1.
† Recombinant mouse calreticulin (CRT) was citrullinated in vitro.
CRT citrullination sites were identified by matrix-assisted laser desorp-
tion ionization–time-of-flight/time-of-flight mass spectrometry (MS).
‡ CRT citrullination sites in cell or tissue extracts were identified by
liquid chromatography electrospray ionization MS/MS.
Figure 1. Calreticulin (CRT) citrullination enhances the interaction
between CRT and the shared epitope (SE) and potentiates SE-
activated signaling. A, Surface plasmon resonance (SPR) data showing
binding interactions between native CRT (N-CRT) or citrullinated
CRT (Cit-CRT) and the SE-positive peptide ligand 65–79*0401 or the
control SE-negative peptide 65–79*0402. The native CRT and Cit-
CRT proteins were immobilized on a biosensor chip at 3,000 response
units (RU), 65–79*0401 and 65–79*0402 were each applied in the
analyte at 330 M, and binding interactions were determined. B, SPR
data showing binding interactions between native CRT or Cit-CRT
and SE-positive (T-0401) or SE-negative (T-1501) tetramers each
applied in the analyte at a 250 nM concentration. C, Nitric oxide (NO)
production by CRT-deficient cells incubated with various concentra-
tions of native CRT or Cit-CRT and 100 g/ml of the SE-positive
peptide 65–79*0401. D, NO production by crt/ mouse cells incu-
bated with 1 g/ml of native CRT or Cit-CRT and various concentra-
tions of the SE-positive peptide 65–79*0401. Data are representative
of at least 2 independent identical experiments. Values in C and D are
the mean  SEM. FU  fluorescence units; NS  not significant.
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analysis of the Cit-CRT used in Figure 1 showed that
these 3 arginine residues were all citrullinated (Table 2).
We therefore theorized that one or more of them may
have contributed to the effects of Cit-CRT. Since citrul-
line is not a genetically coded residue, selective insertion
of individual citrulline residues by recombinant DNA
technology is not possible. We therefore adapted a
site-directed citrulline-simulation approach, by mutating
positively charged arginine residues to neutrally charged
alanines. These substitutions did not introduce confor-
mational changes in CRT, as evidenced by circular
dichroism (see Supplementary Figure 1, available on the
Arthritis & Rheumatism web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.37814/abstract).
Wild-type CRT or its point mutant variants were
immobilized on biosensor chips as described above, and
their binding to the SE peptide ligand or HLA–DR
tetrameric proteins was determined. As Figure 2 shows,
a single arginine-to-alanine substitution in position 205
(R205A) augmented CRT binding to SE-expressing
peptides (Figure 2A) and tetrameric proteins (Figure
2B), while R261A demonstrated diminished binding.
R160A mutation did not have a significant impact on
CRT–SE binding. None of the substitutions had a
significant impact on CRT interaction with SE-negative
peptides or tetramers, confirming the specificity of the
findings. Interestingly, the 2 P-domain arginines, Arg205
and Arg261, had a diametrically opposite effect on SE
binding. To further characterize the relative role of these
arginines, we generated a double mutant expressing both
substitutions (R205A/R261A). As can be seen in Figure
2, the double mutant R205A/R261A retained an en-
hanced interaction with the SE, indicating that Arg205
had a dominant effect.
We next determined the relative role of individ-
ual P-domain arginines on SE-activated signaling. As
can be seen in Figure 2D, the R205A point substitution
significantly enhanced SE-activated signaling, while
other mutations had no significant effect on SE signal-
ing. Collectively, these findings identify the positive
charge of Arg205 as a critical determinant of CRT
function. Neutralization of this single charge led to
markedly enhanced receptor–ligand interaction and sig-
naling. Thus, deimination of Arg205 is the single most
likely protein modification responsible for the effect of
global CRT citrullination. Deimination of the 2 other
arginines, Arg160 and Arg261, does not appear to con-
tribute meaningfully to the net effect of global CRT
citrullination on its SE receptor function.
Overabundance of Cit-CRT in RA synovium. As
a prelude to future investigation of the clinical relevance
of the data discussed above, we sought to determine the
abundance of Cit-CRT in vivo. Figure 3A shows 2-D
protein gels of FLS extracts obtained from representa-
tive RA and OA patients and blotted with anticitrulline
antibodies. A citrullinated acidic protein spot (pI 4.3)
fitting the expected CRT coordinates was found to be
much more abundant in the RA sample than in the OA
sample. When membranes were stripped and blotted
with anti-CRT, the identity of that spot was confirmed as
CRT. The spot in the RA sample showed a unique acidic
Figure 2. Role of individual CRT arginine residues. A, SPR data
showing binding interactions between native CRT, Cit-CRT, or CRT
with selected Arg-Ala substitutions and the SE-positive peptide ligand
65–79*0401 or the control SE-negative peptide 65–79*0402. The CRT
variants were immobilized on a biosensor chip at 3,000 RU, 65–
79*0401 and 65–79*0402 were each applied in the analyte at 330 M,
and binding interactions were determined. B, SPR data showing
binding interactions between the different CRT variants shown in A
and SE-positive (T-0401) or SE-negative (T-1501 and T-0301) tetra-
mers each applied in the analyte at a 250 nM concentration. C, Repre-
sentative sensorgrams of the data shown in B for binding with T-0401.
D, NO production by CRT-deficient cells incubated with CRT or its
variants and the SE-positive peptide 65–79*0401. Data are represen-
tative of at least 2 independent identical experiments. Values in A, B,
and D are the mean  SEM.   P  0.05;   P  0.01;   P 
0.005, versus native CRT in A and B and versus wild-type CRT
(WT-CRT) in D. See Figure 1 for other definitions.
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shift, a feature which is characteristic of citrullinated
proteins.
There was no statistically significant difference in
total CRT abundance between 5 RA and 4 OA synovial
tissue samples (Figure 3B). However, as shown in Figure
3C, RA synovial tissue had a significantly higher relative
abundance of Cit-CRT compared with OA tissue. We
performed a similar analysis on 22 FLS cell lines. As
shown in Figure 3D, RA FLS had a significantly higher
abundance of Cit-CRT compared to OA FLS.
We have also used MS analysis to determine
citrullination changes. Deimination of 1 arginine to
citrulline results in a mass shift of 1 dalton, which is
difficult to detect by standard MS. To overcome this
limitation, we used a chemical modification method,
which involves a reaction of the ureido group of citrul-
line with 2,3-butanedione in the presence of antipyrine
(29). This results in a characteristic mass shift of 238
daltons, which is easier to detect. MS analyses were
performed on samples from 5 RA and 4 OA patients
(Table 2). There was some variability among individual
samples in the repertoire of citrullination sites; however,
we could not identify qualitative differences between
RA and OA samples in this early study. It remains
possible that while there are no qualitative differences
between RA and OA in terms of the repertoire of
citrullinated sites, there could be a quantitative differ-
ence, namely differential abundance of site-specific
deimination. Demonstration of such differences is likely
to require analysis of a very large number of samples.
DISCUSSION
The basis of the association between RA and the
SE and the role of protein citrullination in the disease
are both unknown. We have previously demonstrated
that the SE is a ligand that interacts with cell surface
CRT at a specific binding site in the receptor P-domain
and transduces innate immune signals. In this study we
demonstrated that citrullination of CRT increased its
affinity for the SE ligand and enhanced its signaling
potency. By introducing citrullination-mimicking site-
specific mutations, we were able to demonstrate that
particular arginine residues in the vicinity of the SE
binding site play distinct modulatory roles in SE–CRT
interaction and signal transduction. Further, we demon-
strated, for the first time, that Cit-CRT is overabundant
in RA synovial tissue and synovial tissue–derived FLS.
The findings of this study have dual significance.
First, they provide important insights into the molecular
topology and tridimensional confines of SE–CRT inter-
action, and second, they offer a plausible model that
could explain the pathogenic role of the SE in RA and
the interplay between genetic and nongenetic factors in
the disease.
The impact of citrullination on the SE–CRT
interaction observed here is consistent with previous
reports concerning structural and functional effects of
this posttranslational protein modification. Citrullina-
tion involves deimination of arginine with resultant
conversion to citrulline. Arginine is strongly basic,
whereas citrulline is a charge-neutral residue. Citrullina-
tion therefore introduces net loss in the protein charge,
and consequently could affect interaction with proteins
and other biomolecules (30–33). In addition to the effect
of deimination on the polypeptide primary sequence,
Figure 3. Quantification of synovial Cit-CRT. A, Representative
2-dimensional (2-D) immunoblot display of protein citrullination
patterns in fibroblast-like synoviocytes (FLS) obtained from patients
with rheumatoid arthritis (RA) or osteoarthritis (OA). Left, An acidic
protein fitting CRT 2-D coordinates (boxed area) was found to be
overexpressed in RA. Enlarged images of the spots are shown. Right,
Membranes were stripped and reprobed with anti-CRT antibodies.
The spots (boxed areas) were confirmed as CRT. Enlarged images of
the CRT spots show an acidic shift in the RA sample, consistent with
citrullination. B, CRT:-actin ratio in synovial tissue samples obtained
from patients with RA and patients with OA during joint replacement
surgery. Total protein extracts were separated by polyacrylamide gel
electrophoresis and blotted with anti-CRT and anti–-actin. Levels of
total CRT relative to -actin in crude synovial tissue extracts were not
statistically different between RA and OA samples. C, Cit-CRT index
(the ratio between Cit-CRT and total CRT) in synovial tissue samples
obtained from patients with RA and patients with OA. Abundance of
Cit-CRT in synovial tissue was significantly higher in RA than in OA
samples. D, Cit-CRT index in FLS samples obtained from patients with
RA and patients with OA. Quantification of Cit-CRT in FLS was
performed as described in part C. Values in B–D are the mean  SEM
(n  4 patients with RA and 5 patients with OA). See Figure 1 for
other definitions.
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citrullinated proteins can undergo secondary conforma-
tional changes that influence their access to other mol-
ecules (34).
Of the two mechanisms by which protein citrul-
lination can affect interaction with other molecules, we
tend to favor loss of charge as an underlying mechanism.
As circular dichroism spectra indicate, CRT citrullina-
tion did not produce a significant conformational change
(see Supplementary Figure 1, available on the Arthritis &
Rheumatism web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.37814/abstract). Further, the R205A mu-
tant, with a single substitution, reproduced the effect of
global citrullination, suggesting that a charged moiety
near the SE binding site accounts for most of the
citrullination effect on CRT–SE interaction. Based on
the finding that single substitutions at Arg160 and Arg261
had a neutral or an opposite effect, respectively, we
propose that citrullinated Arg205 may have a dominant
SE binding enhancing effect, which overrides an oppo-
site effect by the more remote Arg261. A proposed model
of the spatial role of P-domain arginine residues on SE
binding is depicted in Figure 4.
Consistent with the SE ligand hypothesis (35–37),
the affinity of SE–CRT interaction correlated with sig-
naling potency. Cit-CRT, which displayed higher affinity
for the SE ligand in a cell-free binding assay, transduced
a markedly more potent signal for production of NO
than did native CRT. Likewise, CRT mutant R205A,
which demonstrated higher SE binding, transduced
more potent SE signaling, while R160A, which did not
significantly affect the interaction with the SE, also did
not produce a significant signaling effect. An interesting
exception to this rule was seen with CRT mutant R261A,
which, despite its significantly weaker interaction with
the SE ligand in cell-free binding assays, maintained
signal transduction potency comparable to that of wild-
type CRT. The reason is unclear, but could conceivably
be related to the fact that the Arg261 side chain is
directed away from the SE binding site (Figure 4). This
dichotomy suggests that citrullination of Arg261 is less
likely to impact SE biologic effects in physiologic condi-
tions. The specificity of the impact of citrullination
changes around the SE binding site indicate that aug-
mented SE–CRT binding, rather than nonspecific in-
creased signaling by Cit-CRT, is responsible for the
observed effect on SE-activated signaling.
We found no measurable differences in the abun-
dance of total CRT between OA and RA samples.
However, the fraction of Cit-CRT of total CRT was
significantly higher in RA. These data corroborate and
expand on a brief prior observation that Cit-CRT is
overexpressed in the serum of patients with early RA
(38). The data shown here are the first indication that
the synovial tissue itself, the primary disease focus in
RA, overexpresses this posttranslationally modified pro-
tein. It is important to note that abundance of citrulli-
nated proteins in pathologic tissue is not unique to RA,
and has been reported in many other conditions, such as
multiple sclerosis, Alzheimer’s disease, and Crohn’s
disease (11,39). The cause of excessive protein citrulli-
nation in pathologic tissue is unclear, but could be a
consequence of cell death (40) or oxidative stress (41).
Citrullinated proteins may contribute directly to
the disease process, rather than be only a consequence
of inflammation (42). However, unlike all other condi-
tions in which citrullinated proteins have been found, in
RA these proteins act as neoantigens and trigger an
autoantibody response (ACPA). The strong association
between ACPAs and RA, the appearance of these
autoantibodies prior to disease onset, and their associa-
tion with SE and smoking have led many to suggest that
ACPAs may play a direct pathogenic role in RA (43).
Figure 4. A model of CRT–SE interaction. The SE ligand (cyan)
interacts with Glu217, Asp220 and Glu223 (pink), previously identified as
the SE binding site in the CRT P-domain (orange) (8). P-domain
Arg205 and Arg261 are shown in green. The CRT Arg205 side chain
points toward the SE, and reaches a distance of 3.1Å from the SE. The
model proposed here predicts that this positively charged moiety
exerts an inhibitory effect on CRT–SE interaction. Citrullination of
Arg205 may therefore decrease a putative hindrance and increase
binding affinity. Arg261, in contrast, points away from the SE binding
site at a predicted distance of 12.9Å, in an orientation that cannot
inhibit SE–CRT interaction. We propose that the enhancing effect of
Arg261 on SE–CRT binding could be related to charge-based interac-
tion with other parts of the HLA–DR molecule, or a stabilizing effect
on CRT spatial conformation. The functionally inert residue Arg160 is
located in the N-domain at a distance of 24.7Å from the SE binding
site (not shown). See Figure 1 for definitions.
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Some evidence in support of this hypothesis has been
documented in experimental murine models of arthritis
(44,45).
It has previously been reported that SE-
expressing HLA–DR molecules can bind and present
citrullinated peptides (46,47). Given that observation,
could Cit-CRT peptides be preferentially presented by
SE-expressing DR molecules in RA and generate
ACPAs? The findings of this study cannot refute or
substantiate that scenario. However, it is important to
point out that presentation of Cit-CRT peptides is not
the underlying mechanism of our findings for several
reasons. First, we used different allele-specific tetram-
ers, all of which contain a uniform, covalently bound
groove CLIP peptide. It is highly unlikely that these
tetramers would be able to present other peptides.
Likewise, synthetic SE peptides in solution are incapable
of antigen presentation. Second, we are not aware of
reports of autoantibodies to Cit-CRT, while there are
many other Cit-peptides that are known to be immuno-
genic in RA (citrullinated fibrinogen, citrullinated vi-
mentin, etc.). We therefore believe it is not necessary to
postulate that Cit-CRT might be the autoantigen that
drives the anti–cyclic citrullinated peptide response.
This study did not set out to explain the genesis of
ACPAs, and therefore we cannot determine the cause–
effect relationship between SE-activated signaling and
ACPAs. However, it should be pointed out that in a
recent study we demonstrated that the SE–CRT path-
way leads to immune dysregulation that diminishes Treg
cell numbers, and reciprocally enhances Th17 expansion
(7). It remains to be determined whether SE-mediated
immune dysregulatory effect can facilitate autoimmune
responses, such as ACPAs.
Independent of the putative pathogenic role of
ACPAs, the findings of this study could help to better
explain the interaction between inherited and acquired
factors in RA. Epidemiologic data strongly suggest that
an interaction between genetic (SE) and nongenetic
factors may be involved. Here we identified an acquired,
possibly environmentally induced event that substan-
tially amplified the functional effect of a genetically
determined factor, the SE. It is therefore tempting to
propose that the SE functional effect in RA may be
facilitated by site-specific citrullinated CRT. Thus, in
healthy individuals carrying SE-encoding HLA–DRB1
alleles, the SE ligand interacts at low affinity with cell
surface CRT that is largely noncitrullinated. This inter-
action could be beneficial by activating low-grade Th17
polarization (7), which could be advantageous against
pathogens (48). As a result of environmental stresses
(for example, long-term exposure to cigarette smoke),
there could be a gradual activation of PAD with resul-
tant citrullination of many proteins, including CRT. As
the abundance of Cit-CRT gradually increases, it could
reach a critical threshold, when the affinity to the SE
results in exaggerated signaling with resultant pathology.
In individuals with the right constellation of genetic risk
factors, the combined scenario described above could
trigger disease onset.
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